Skip to main content

Loading market data...

PTCT

PTC Therapeutics, Inc.

NASDAQ • United states

$62.62

-$0.30

(-0.48%)

Source: Yahoo Finance · Quote time Oct 21, 2026 20:00 GMT+0000

Management
Credibility
Score

PTC Therapeutics, Inc. (PTCT)

Unavailable

Quotes may be delayed

$5.23B

Market Cap

943,876

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

PTC Therapeutics, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

22 Sep 2026

PTC Therapeutics, Inc. reported Regulation FD disclosure

PTC Therapeutics, Inc. filed an 8-K covering Regulation FD disclosure, another company event, supporting financial statements or exhibits.

29 Aug 2026

PTC Therapeutics, Inc. reported A material agreement

PTC Therapeutics, Inc. filed an 8-K covering a material agreement.

13 Aug 2026

PTC Therapeutics, Inc. reported Regulation FD disclosure

PTC Therapeutics, Inc. filed an 8-K covering Regulation FD disclosure, another company event, supporting financial statements or exhibits.

31 Jul 2026

PTC Therapeutics, Inc. filed Form 10-Q

PTC Therapeutics, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

31 Jul 2026

PTC Therapeutics, Inc. reported Operating or financial results

PTC Therapeutics, Inc. filed an 8-K covering operating or financial results, a director or senior management change or compensation event, Regulation FD disclosure, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$1.05B

Total assets (USD)$3.25B

Total liabilities (USD)$3.42B

Shareholders' equity (USD)−$165.36M

Long-term debt (USD)$535.52M

Debt due within a year (USD)$55.45M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$360.52M	$148.98M	$83.50M	$0.92	10-Q · 30 Jul 2026
Q1 2026	$272.55M	$44.96M	−$2.81M	−$0.03	10-Q · 7 May 2026
Q4 2025	$164.68M	−$71.35M	−$134.61M	Unavailable	10-K · 19 Feb 2026
Q3 2025	$211.01M	$3.02M	$15.90M	$0.20	10-Q · 4 Nov 2025
Q2 2025	$178.88M	−$34.96M	−$64.85M	−$0.83	10-Q · 7 Aug 2025
Q1 2025	$1.18B	$970.23M	$866.56M	$10.04	10-Q · 6 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $96.64

54.3% upside potential

📈

Strong Buy

Unavailable

👍

Buy

10

⏸️

Hold

1

📉

Sell

1

12 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 22 Oct 2026, 06:49 UTC Targets range 62.00–137.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

14

Oct 2026

SCHMERTZLER MICHAEL

Director

Open-market sale

$59.61 per share

2,500 shares

9

Oct 2026

Boulding Mark Elliott

EXEC. VP AND CLO

Option exercise

$39.42 per share

192 shares

9

Oct 2026

Boulding Mark Elliott

EXEC. VP AND CLO

Open-market sale

$64.26 per share

192 shares

7

Oct 2026

SCHMERTZLER MICHAEL

Director

Open-market sale

$63.39 per share

2,500 shares

6

Oct 2026

Boulding Mark Elliott

EXEC. VP AND CLO

Option exercise

$39.42 per share

435 shares

6

Oct 2026

Boulding Mark Elliott

EXEC. VP AND CLO

Open-market sale

$64.16 per share

435 shares

5

Oct 2026

Boulding Mark Elliott

EXEC. VP AND CLO

Option exercise

$39.42 per share

1,638 shares

5

Oct 2026

Boulding Mark Elliott

EXEC. VP AND CLO

Open-market sale

$64.03 per share

1,638 shares

30

Sep 2026

STEELE GLENN JR MD PHD

Director

Option exercise

$11.23 per share

12,000 shares

30

Sep 2026

STEELE GLENN JR MD PHD

Director

Open-market sale

$65.16 per share

12,000 shares

Top Shareholders

Blackrock, Inc.

13,964,554 shares

7.845% change

6/30/2026

Vanguard Group Inc

8,803,203 shares

6.203% change

12/31/2025

Rtw Investments, Lp

7,746,415 shares

0% change

6/30/2026

Jupiter Topco Llc

7,236,402 shares

New% change

6/30/2026

Janus Henderson Group Ltd.

7,193,433 shares

48.277% change

3/31/2026

Vanguard Portfolio Management Llc

4,928,111 shares

2.571% change

6/30/2026

State Street Corp

4,598,952 shares

5.808% change

6/30/2026

Wellington Management Group Llp

4,128,273 shares

4.709% change

6/30/2026

Vanguard Capital Management Llc

3,739,127 shares

1.71% change

6/30/2026

Geode Capital Management, Llc

2,207,376 shares

-0.117% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 22 Oct 2026, 06:49 UTC· 59 minutes ago

Research coverage and investment tools

PTC Therapeutics, Inc. (PTCT) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$62.62 on 21 Oct 2026. That is 12% of the way from its 52-week low of US$58.80 to its 52-week high of US$90.87. Its market capitalisation was US$5.23 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$360.52M	$148.98M	$83.50M	$0.92	—	41.3%	$126.92M	10-Q · 30 Jul 2026 (opens in a new tab)
Q1 2026	$272.55M	$44.96M	−$2.81M	−$0.03	—	16.5%	−$60.24M	10-Q · 7 May 2026 (opens in a new tab)
Q4 2025	$164.68M	−$71.35M	−$134.61M	Unavailable	—	-43.3%	−$36.65M	10-K · 19 Feb 2026 (opens in a new tab)
Q3 2025	$211.01M	$3.02M	$15.90M	$0.20	—	1.4%	−$69.82M	10-Q · 4 Nov 2025 (opens in a new tab)
Q2 2025	$178.88M	−$34.96M	−$64.85M	−$0.83	—	-19.5%	−$59.58M	10-Q · 7 Aug 2025 (opens in a new tab)
Q1 2025	$1.18B	$970.23M	$866.56M	$10.04	—	82.5%	$868.38M	10-Q · 6 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	7/30/2026	$0.92	−$0.17	+641.2%
Mar 2026	5/7/2026	−$0.03	−$0.45	+93.3%
Dec 2025	2/19/2026	−$1.67	−$0.21	-695.2%
Sep 2025	11/4/2025	$0.20	−$1.19	+116.8%

Cash and equivalents: $1.05B
Total assets: $3.25B
Total liabilities: $3.42B
Shareholders' equity: −$165.36M
Long-term debt: $535.52M
Debt due within a year: $55.45M

8-K · 22 Sep 2026

PTC Therapeutics, Inc. reported Regulation FD disclosure (opens in a new tab)

PTC Therapeutics, Inc. filed an 8-K covering Regulation FD disclosure, another company event, supporting financial statements or exhibits.
8-K · 29 Aug 2026 · Material agreement Signed

PTC Therapeutics, Inc. reported A material agreement (opens in a new tab)

PTC Therapeutics, Inc. filed an 8-K covering a material agreement.
8-K · 13 Aug 2026

PTC Therapeutics, Inc. reported Regulation FD disclosure (opens in a new tab)

PTC Therapeutics, Inc. filed an 8-K covering Regulation FD disclosure, another company event, supporting financial statements or exhibits.
10-Q · 31 Jul 2026

PTC Therapeutics, Inc. filed Form 10-Q (opens in a new tab)

PTC Therapeutics, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 31 Jul 2026

PTC Therapeutics, Inc. reported Operating or financial results (opens in a new tab)

PTC Therapeutics, Inc. filed an 8-K covering operating or financial results, a director or senior management change or compensation event, Regulation FD disclosure, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
SCHMERTZLER MICHAEL Director	14 Oct 2026	Open-market sale (S)	−2,500	$59.61	Form 4 (opens in a new tab)
Boulding Mark Elliott EXEC. VP AND CLO	9 Oct 2026	Option exercise (M)	+192	$39.42	Form 4 (opens in a new tab)
Boulding Mark Elliott EXEC. VP AND CLO	9 Oct 2026	Open-market sale (S)	−192	$64.26	Form 4 (opens in a new tab)
SCHMERTZLER MICHAEL Director	7 Oct 2026	Open-market sale (S)	−2,500	$63.39	Form 4 (opens in a new tab)
Boulding Mark Elliott EXEC. VP AND CLO	6 Oct 2026	Option exercise (M)	+435	$39.42	Form 4 (opens in a new tab)
Boulding Mark Elliott EXEC. VP AND CLO	6 Oct 2026	Open-market sale (S)	−435	$64.16	Form 4 (opens in a new tab)
Boulding Mark Elliott EXEC. VP AND CLO	5 Oct 2026	Option exercise (M)	+1,638	$39.42	Form 4 (opens in a new tab)
Boulding Mark Elliott EXEC. VP AND CLO	5 Oct 2026	Open-market sale (S)	−1,638	$64.03	Form 4 (opens in a new tab)
STEELE GLENN JR MD PHD Director	30 Sep 2026	Option exercise (M)	+12,000	$11.23	Form 4 (opens in a new tab)
STEELE GLENN JR MD PHD Director	30 Sep 2026	Open-market sale (S)	−12,000	$65.16	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	13,964,554	7.845%
Vanguard Group Inc	12/31/2025	8,803,203	6.203%
Rtw Investments, Lp	6/30/2026	7,746,415	0%
Jupiter Topco Llc	6/30/2026	7,236,402	New
Janus Henderson Group Ltd.	3/31/2026	7,193,433	48.277%
Vanguard Portfolio Management Llc	6/30/2026	4,928,111	2.571%
State Street Corp	6/30/2026	4,598,952	5.808%
Wellington Management Group Llp	6/30/2026	4,128,273	4.709%
Vanguard Capital Management Llc	6/30/2026	3,739,127	1.71%
Geode Capital Management, Llc	6/30/2026	2,207,376	-0.117%

Previous close: 62.92 USD
Day range: 62.41 – 63.74 USD
52-week range: 58.80 – 90.87 USD
Volume: 943,876
Market cap: $5.23B
Average volume: 1,036,527
EPS (FY 2025, diluted): 7.78 USD
Shares outstanding: 83.46M
Beta (5Y monthly): 0.50

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 20:00 UTC· 11 hours ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:30 UTC· 1 hour ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for PTCT yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.